M
Marin Kautz
Researcher at Temple University
Publications - 31
Citations - 882
Marin Kautz is an academic researcher from Temple University. The author has contributed to research in topics: Medicine & Randomized controlled trial. The author has an hindex of 12, co-authored 22 publications receiving 494 citations. Previous affiliations of Marin Kautz include Columbia University Medical Center & Icahn School of Medicine at Mount Sinai.
Papers
More filters
Journal ArticleDOI
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
James W. Murrough,Laili Soleimani,Kaitlin E. DeWilde,Katherine A. Collins,Kyle A. Lapidus,Brian M. Iacoviello,Marc S. Lener,Marin Kautz,J. Kim,J. B. Stern,Rebecca B. Price,Andrew M. Perez,Jess W. Brallier,G. J. Rodriguez,Wayne K. Goodman,Dan V. Iosifescu,Dennis S. Charney +16 more
TL;DR: The current findings provide initial support for the safety and tolerability of ketamine as an intervention for SI in patients who are at elevated risk for suicidal behavior.
Journal ArticleDOI
A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder
Adriana Feder,Sara Costi,Sarah B Rutter,Abigail B Collins,Usha Govindarajulu,Manish K. Jha,Sarah R. Horn,Marin Kautz,Morgan Corniquel,Katherine A. Collins,Laura Bevilacqua,Andrew M Glasgow,Jess W. Brallier,Robert H. Pietrzak,James W. Murrough,Dennis S. Charney +15 more
TL;DR: In this paper, the authors present a proof-of-concept randomized clinical trial for posttraumatic stress disorder (PTSD) using pharmacotherapies, which showed that they have limited efficacy.
Journal ArticleDOI
Acetyl-l-carnitine deficiency in patients with major depressive disorder.
Carla Nasca,Benedetta Bigio,Francis S. Lee,Sarah P. Young,Marin Kautz,Ashly Albright,James Beasley,David S. Millington,Aleksander A. Mathé,James H. Kocsis,James W. Murrough,Bruce S. McEwen,Natalie L. Rasgon,Natalie L. Rasgon +13 more
TL;DR: For example, this paper found that LAC levels, and not those of free carnitine, were decreased in patients with major depressive disorder compared with age-and sex-matched healthy controls in two independent study centers.
Journal ArticleDOI
Neuropeptide Y, resilience, and PTSD therapeutics
TL;DR: The evidence base for targeting the NPY system as a therapeutic approach in PTSD is reviewed, and impediments and potential solutions to therapeutic development are considered.
Journal ArticleDOI
Insulin receptor substrate in brain-enriched exosomes in subjects with major depression: on the path of creation of biosignatures of central insulin resistance.
Carla Nasca,Josh Dobbin,Benedetta Bigio,Kathleen T. Watson,Paolo de Angelis,Marin Kautz,Ashly Cochran,Aleksander A. Mathé,James H. Kocsis,Francis S. Lee,James W. Murrough,Bruce S. McEwen,Natalie L. Rasgon,Natalie L. Rasgon +13 more
TL;DR: An increased number of exosomes enriched for L1CAM, a marker predominantly expressed in the brain, in subjects with major depressive disorder (MDD) as compared with age- and sex-matched healthy controls (HC) and increased concentration of the insulin receptor substrate-1 (IRS-1), which is associated with suicidality and anhedonia, are reported.